Table 3.
Allele and genotype frequencies of TNF -308 and -863 SNPs and association between HLA-DR15 and TNF SNPs in Caucasian patients with MDS or CML.
| MDS | CML | |
|---|---|---|
| TNF -308 alleles* | ||
| A | 120/375 (32%) | 181/593 (30.5%) |
| G | 366/375 (97.6%) | 577/593 (97.3%) |
| Genotypes | ||
| AA | 9/375 (2.4%) | 16/593 (2.7%) |
| AG | 111/375 (29.6%) | 165/593 (27.8%) |
| GG | 255/375 (68%) | 412/593 (69.5%) |
| TNF -863 alleles* | ||
| A | 115/372 (30.7%) | 165/593 (27.8%) |
| C | 358/372 (95.5%) | 582/593 (98.1%) |
| Genotypes | ||
| AA | 14/372 (3.8%) | 11/593 (1.9%) |
| AC | 101/372 (27.2%) | 154/593 (26.0%) |
| CC | 257/372 (69.1%) | 428/593 (72.2%) |
| Proportion of DR15-positive patients | |||
|---|---|---|---|
| MDS | CML | Chi-square p-value, MDS, CML | |
| TNF -308 | |||
| AA | 0/9 | 2/16 (12.5%) | p=.003, p=.54 |
| AG | 26/111 (23.4%) | 37/165 (22.4%) | |
| GG | 97/255 (38.0%) | 99/412 (24.0%) | |
| TNF -863 | |||
| AA | 5/14 (35.7%) | 0/11 | p=.11, p=.03 |
| AC | 25/101 (24.8%) | 28/154 (18.2%) | |
| CC | 93/257 (36.2%) | 110/428 (25.7%) | |
CML=chronic myeloid leukemia; MDS=myelodysplastic syndrome; TNF=tumor necrosis factor α; SNP = single nucleotide polymorphism.
*
heterozygotes contribute to both allele categories